XOMA XOMA Royalty Corp.
HealthcareAs of 2026-05-26
Valuation
View DetailsP/E (TTM)
14.00
PEG
0.04
P/B
4.39
P/S
14.42
EV/EBITDA
13.20
DCF Value
$-49.65
FCF Yield
1.3%
Div Yield
0.0%
Margins & Returns
Gross Margin
93.3%
Operating Margin
13.7%
Net Margin
87.0%
ROE
30.2%
ROA
11.6%
ROIC
1.9%
Financials
View All| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 null | $12.3M | $4.5M | $— |
| Q4 null | $1.4M | $6.1M | $— |
| FY null | $52.1M | $31.7M | $— |
| Q3 null | $9.4M | $14.1M | $— |
Analyst Ratings
View AllConsensus
Hold
Target (Consensus)
$53.75
Target (Median)
$50.00
Target Range
$39.00 - $76.00
Trading Activity
Insider Trades
View AllCompany Info
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
—
Beta
0.90
XOMA Royalty Corp. operates as a biotechnology royalty aggregator in Europe, the United States, and the Asia Pacific. The company engages in helping biotech companies for enhancing human health. It acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceutical or biotechnology companies. The company focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners. It has a portfolio with approximately 70 assets. XOMA Corporation was incorporated in 1981 and is headquartered in Emeryville, California.